• Something wrong with this record ?

The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial-Study Design and Protocol

P. Novodvorský, L. Thieme, I. Laňková, M. Mráz, ZJ. Taybani, B. Bótyik, P. Stella, M. Vytasil, F. Lauand, M. Bonnemaire, M. Haluzík

. 2024 ; 15 (6) : 1461-1471. [pub] 20240424

Status not-indexed Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24012653

Grant support
This is an investigator-initiated study which is supported by Sanofi. Sanofi

INTRODUCTION: Multiple daily injection insulin regimen (MDI) represents the most intensive insulin regimen used in the management of people with type 2 diabetes (PwT2D). Its efficacy regarding glycaemic control is counterbalanced by the increased risk of hypoglycaemia, frequently observed tendency to weight gain and necessity for frequent glucose monitoring. Recent introduction of novel antidiabetic medications with pleiotropic effects reaching far beyond the reduction of glycaemia (HbA1c), such as the glucagon-like peptide 1 receptor agonist (GLP-1 RA), has significantly widened the therapeutic options available for management of T2D. Consequently, there is currently a substantial number of PwT2D for whom the MDI regimen was initiated at a time when no other options were available. Yet, in present times, these individuals could benefit from simplified insulin regimens ideally taking advantage of the beneficial effects of the novel classes of antidiabetic medications. iGlarLixi (Suliqua®) is a once-daily fixed-ratio combination of basal insulin analogue glargine 100 U/ml and a GLP-1 RA lixisenatide. METHODS: Insulin therapy DE-intensificAtion with iglarLixi (IDEAL) is a six-centre, open-label, parallel-group, active comparator, phase IV randomised controlled trial with a 24-week active treatment period examining the efficacy and safety of MDI regimen de-intensification with once-daily administration of iGlarLixi versus MDI regimen continuation in PwT2D on a backgroud therapy with metformin ± sodium-glucose cotransporter 2 inhibitor. PLANNED OUTCOMES: The primary objective is to compare the effects of MDI therapy de-intensification with iGlarLixi versus MDI regimen continuation regarding glycaemic control (HbA1c). Secondary objectives include detailed evaluation of the effects of MDI regimen de-intensification with iGlarLixi on glycaemic control using standardised continuous glucose monitoring (CGM) metrics and self-monitoring of plasma glucose. Furthermore, body weight and body composition analysis, quality of life and safety profile are evaluated. TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT04945070.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012653
003      
CZ-PrNML
005      
20240726151410.0
007      
ta
008      
240723s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13300-024-01582-x $2 doi
035    __
$a (PubMed)38653903
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Novodvorský, Peter $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic $u Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK $1 https://orcid.org/0000000232927586 $7 xx0275745
245    14
$a The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial-Study Design and Protocol / $c P. Novodvorský, L. Thieme, I. Laňková, M. Mráz, ZJ. Taybani, B. Bótyik, P. Stella, M. Vytasil, F. Lauand, M. Bonnemaire, M. Haluzík
520    9_
$a INTRODUCTION: Multiple daily injection insulin regimen (MDI) represents the most intensive insulin regimen used in the management of people with type 2 diabetes (PwT2D). Its efficacy regarding glycaemic control is counterbalanced by the increased risk of hypoglycaemia, frequently observed tendency to weight gain and necessity for frequent glucose monitoring. Recent introduction of novel antidiabetic medications with pleiotropic effects reaching far beyond the reduction of glycaemia (HbA1c), such as the glucagon-like peptide 1 receptor agonist (GLP-1 RA), has significantly widened the therapeutic options available for management of T2D. Consequently, there is currently a substantial number of PwT2D for whom the MDI regimen was initiated at a time when no other options were available. Yet, in present times, these individuals could benefit from simplified insulin regimens ideally taking advantage of the beneficial effects of the novel classes of antidiabetic medications. iGlarLixi (Suliqua®) is a once-daily fixed-ratio combination of basal insulin analogue glargine 100 U/ml and a GLP-1 RA lixisenatide. METHODS: Insulin therapy DE-intensificAtion with iglarLixi (IDEAL) is a six-centre, open-label, parallel-group, active comparator, phase IV randomised controlled trial with a 24-week active treatment period examining the efficacy and safety of MDI regimen de-intensification with once-daily administration of iGlarLixi versus MDI regimen continuation in PwT2D on a backgroud therapy with metformin ± sodium-glucose cotransporter 2 inhibitor. PLANNED OUTCOMES: The primary objective is to compare the effects of MDI therapy de-intensification with iGlarLixi versus MDI regimen continuation regarding glycaemic control (HbA1c). Secondary objectives include detailed evaluation of the effects of MDI regimen de-intensification with iGlarLixi on glycaemic control using standardised continuous glucose monitoring (CGM) metrics and self-monitoring of plasma glucose. Furthermore, body weight and body composition analysis, quality of life and safety profile are evaluated. TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT04945070.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Thieme, Lenka $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic
700    1_
$a Laňková, Ivana $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic
700    1_
$a Mráz, Miloš $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Taybani, Zoltán J $u First Department of Endocrinology, Dr. Réthy Pál Member Hospital, Békes County Central Hospital, Békéscsaba, Hungary
700    1_
$a Bótyik, Balázs $u First Department of Endocrinology, Dr. Réthy Pál Member Hospital, Békes County Central Hospital, Békéscsaba, Hungary
700    1_
$a Stella, Péter $u Sanofi Hungary, Budapest, Hungary
700    1_
$a Vytasil, Miroslav $u Sanofi, Prague, Czech Republic
700    1_
$a Lauand, Felipe $u General Medicines, Sanofi, Paris, France
700    1_
$a Bonnemaire, Mireille $u General Medicines, Sanofi, Paris, France
700    1_
$a Haluzík, Martin $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21, Prague 4, Czech Republic. halm@ikem.cz $u First Faculty of Medicine, Charles University, Prague, Czech Republic. halm@ikem.cz $1 https://orcid.org/0000000202016888 $7 xx0000707
773    0_
$w MED00194311 $t Diabetes therapy $x 1869-6953 $g Roč. 15, č. 6 (2024), s. 1461-1471
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38653903 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151402 $b ABA008
999    __
$a ok $b bmc $g 2125435 $s 1224516
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 15 $c 6 $d 1461-1471 $e 20240424 $i 1869-6953 $m Diabetes therapy $n Diabetes Ther $x MED00194311
GRA    __
$a This is an investigator-initiated study which is supported by Sanofi. $p Sanofi
LZP    __
$a Pubmed-20240723

Find record

Citation metrics

Archiving options